Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | IL1B | P01584 | 5/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910760 | 1.00 | LOXL2 (0.39) | LOXL2HTR3ASYKSCN9AKDR | |
| SCHEMBL15910903 | 0.88 | LOXL2 (0.47) | LOXL2SYKKDRAURKBDDB1 | |
| SCHEMBL15910593 | 0.82 | ALDH1A1 (0.38) | LOXL2SYKKDRAURKBDDB1 | |
| SCHEMBL15910562 | 0.80 | MEN1 (0.38) | LOXL2HTR3ASYKSRCDDB1 | |
| SCHEMBL30098886 | 0.79 | OPRL1 (0.40) | — | |
| SCHEMBL17422116 | 0.76 | HTR6 (0.43) | HTR3AKDRLCKDDB1CRBN | |
| SCHEMBL25939067 | 0.75 | DRD2 (0.43) | HTR3ASRC | |
| SCHEMBL15997927 | 0.74 | HTR3A (0.52) | HTR3ASYKKDRAURKBP2RX7 | |
| SCHEMBL16812514 | 0.73 | TYK2 (0.41) | HTR3ASCN9ASCN10ALCKSRC | |
| SCHEMBL20688516 | 0.73 | TYK2 (0.41) | HTR3ASCN9ASCN10ALCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2762476-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | SYK, BTK, JAK2 | LOXL2 2790/4885HTR3A 743/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.